For & Against

Claude View

Verdict — What's Next, and My Lean

AMR trades at $190 after a 162% 12-month range ($97 low to $254 high) on the same asset base. The specialists agree on the structure (pure-play met coal, net cash, cost discipline) and disagree on what the next 6 months reward: Warren and Quant frame the setup as a trough-cycle call option with margin-per-ton as the single variable; Sherlock reads the insider tape as high-conviction buying into that trough; Historian flags that the capital-return narrative already broke once and could again. This page resolves the tension into a soft lean and a watchlist.

**One-line synthesis:** A debt-free, pure-play met coal producer, priced near cycle trough, with two independent directors buying ~$27M of stock in the open market, a confirmed 45X tax credit that is not yet in consensus numbers, and a Q1-26 print due within weeks that will tell you whether the 2026 contract book is defendable. The thing that tips the scale is the insider tape.

Tab A — What's Next (Next 3–6 Months)

The calendar below is ranked by how much each event can move the stock, not chronologically. Q1 2026 earnings are the near-term hinge; 45X realization and Kingston Wildcat first coal are the 2H26 swing factors.

No Results

Earnings & consensus snapshot

Consensus PT ($)

$201.62

B.Riley PT (Mar-26)

$207

Implied Upside (%)

Street is cautiously constructive but still bruised: Q4-25 EPS missed consensus by 82% on revenue of $520M vs $551M expected. The consensus target ($201.62) sits ~6% above spot. B.Riley's $207 target (raised post-miss on Mar 5) is the freshest datapoint.

Options-implied move

No Results

November 2026 options (longest-dated available — AMR has no true 12-month LEAPS) trade at ~62% implied vol — consistent with a name that has done ±50% in six months twice. A $35 upside move to $225 is ~0.7σ at 7 months out. The option market is not pricing a directional view, which is consistent with "cycle uncertain" rather than "cycle resolved."

If a multi-quarter thesis is what you want to express, sizing the common directly is more capital-efficient than buying 7-month calls at 62% IV. Open interest across the Nov-26 chain is thin (0–30 contracts at most strikes), so expressing a meaningful options position requires patience.

Tab B — For / Against / My View

For (bull case, 3 bullets, each anchored to a specialist)

**1. Insider buying is the cleanest alignment signal this cycle has produced.** Sherlock: Courtis spent ~$20M and Gorzynski ~$7M in open-market purchases at $175–$194 between Dec-25 and Mar-26. Historian cross-confirms via SEC Form 4 cluster and four Motley Fool / Investing.com pieces framing it as a director "increasing exposure at a relative valuation low." Two independent directors, ~$27M personal capital, sub-trough prices — this is not routine.

2. The balance sheet insulates the equity through any reasonable commodity scenario. Quant: $359M net cash, $7M debt, 4.47× current ratio, S&P upgrade to BB- in Dec-24. Warren: AMR can run at $15/ton margin for years and survive. AMR's P/B is 1.57× vs HCC at 2.11× for comparable cycle exposure and more leverage — the balance-sheet premium is not in the quote.

3. A new tax credit and a high-quality volume ramp both land in 2026, and neither is fully in consensus. Warren + Historian: Section 45X adds $30–50M/yr of refundable cash through 2029. Kingston Wildcat (low-vol, scarce product, premium pricing) begins contributing ~500Kt in 2026 ramping toward 1Mt. The combination raises normalized FCF without requiring a spot-price recovery — and the first 45X print has not yet hit the tape.

Against (bear case, 3 bullets, each anchored to a specialist)

**1. Capital-return credibility already broke once, and the vocabulary change is real.** Historian: fixed dividend killed Q4-23, buyback suspended 17 months (Mar-24 to Aug-25), FY25 returns $52M vs $656M in FY23. The FY25 MD&A no longer leads with "shareholder returns" — it leads with "cost discipline." Anyone buying the stock as a cash-return vehicle is buying a 2022–23 story that no longer describes operating behavior.

2. Operating reality is still deteriorating, not stabilizing. Quant: five consecutive quarters of GAAP losses, Q4-25 FCF was negative $9.8M, inventory rose to $193M (9% of revenue — volume not clearing at index). Warren: margin compressed 78% in two years. Two mine fatalities in five months (Rolling Thunder Nov-25, Horse Creek Eagle Apr-26) add regulatory scrutiny and ~$6M of non-recurring cost on top of an already cost-stressed operation.

3. Kingston Wildcat already slipped once, and pay is cyclically sticky. Historian: promised "late 2025 first production" in the 2024 deck — now ~500Kt in 2026 vs 1Mt capacity (a 6–12 month slip). Sherlock: CEO SCT pay fell only 16% YoY while adjusted EBITDA collapsed 70% and the company printed a loss; the comp committee could have zeroed the AIB bonus and did not. Neither is catastrophic alone — together they point to "discipline on costs, less discipline on alignment."

My View

**Lean: cautious-bullish.** At $190, AMR is a trough-cycle call option on through-cycle met margins with a clean balance sheet, a quantified tax-credit uplift, and two independent directors personally long to the tune of eight figures each — that is a rare combination and it is the thing that tips the scale for me. The one condition that flips it: if the Q1-26 print shows committed/priced volume *below* $125/ton on a higher mix percentage, it says contracting season failed and 2026 is another loss year, in which case the insider buys become premature rather than prescient.

Watchlist — the specific things to watch to flip the lean

No Results

**Where the specialists disagree, explicitly.** Warren frames the business as "high-quality, cost-competitive, net-cash pure-play" (structural bull). Quant shows five quarters of losses, negative FCF in Q4-25, and inventory building (near-term bear). Sherlock sees "the clearest possible alignment signal" in the Courtis/Gorzynski buying (bull). Historian documents the capital-return credibility break and the Kingston Wildcat slip (bear). The synthesis is not "average the specialists" — it is: *the business is fine, the cycle is ugly, and the insiders think the cycle turns before the damage compounds*. If you disagree with the insiders, do not own this.

Sizing frame

At a through-cycle $50/ton margin (the number Warren anchors), AMR is worth roughly $160 — below spot. At $75/ton (historical mid-cycle), roughly $250. The spot price of $190 is the market's weighted average of those two scenarios, with a tail on both ends. The insider buying says the odds on $75 are higher than the market is pricing. I agree, with less conviction.

**Final read:** Own a core position, keep dry powder for a second leg down if Q1-26 disappoints, and require Courtis and Gorzynski to remain holders. If either sells within 12 months of buying, the thesis is broken and the position comes off.